

Efficacy and Tolerability of Novel Topical Pigment-Correcting Serums With Biweekly Diamond Tip Microdermabrasion Treatments on Facial Hyperpigmentation (HP), Including Melasma and Post-inflammatory HP

Lisa Goberdhan, MSHS; Katie Schneider, BS; Elizabeth T. Makino, BS, CCRA, MBA; Rahul C. Mehta, PhD

Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA

OBJECTIVE

To assess the cosmetic changes after a combination of a series of 6 DiamondGlow treatments with a novel brightening infusion serum (DGHP) and a take-home regimen including LYT3 and Spot Tx in subjects with mild to severe facial hyperpigmentation

CONCLUSIONS

DiamondGlow HP in combination with LYT3 and Spot Tx was well tolerated and provided immediate skin hydration improvements in subjects with mild to severe HP

Significant improvements in overall HP, MASI score, facial roughness and radiance, and pigmentation parameters of participants' most-bothersome spot were observed throughout the study

This combination in-office and at-home regimen was consistently highly rated by participants

For additional information or to obtain a PDF of this poster



Scan QR code or use the following link to download an electronic version of this presentation and other Allergan Aesthetics and AbbVie 2023 Winter CDC scientific presentations:

<https://abbvie1.outsystemsenterprise.com/GMAEventPublications/Assets.aspx?ConferenceId=526>

QR code expiration: December 13, 2023.

To submit a medical question, please visit www.abbviemedinfo.com

SYNOPSIS


- Hyperpigmentation (HP) refers to increased pigmentation of the skin, such as post-inflammatory HP, melasma, and dark spots, that can be challenging to treat and distressing to patients¹⁻³
- We conducted a 12-week, open-label, single-center study in females with mild to severe facial HP to assess the tolerability and effectiveness of a combination of 6 DiamondGlow treatments with a novel brightening infusion serum (DGHP) and a take-home regimen consisting of LYT3 (novel hydroquinone [HQ]-free, multimodal, pigment-correcting serum) and Spot Tx (novel pigment-correcting spot treatment gel suspension cream)
- After 12 weeks of treatment, DiamondGlow HP in combination with LYT3 and Spot Tx was well tolerated and provided immediate skin hydration improvements as well as significant improvements in overall HP, Melasma Area and Severity Index (MASI) score, facial roughness and radiance, and pigmentation parameters of participants' most-bothersome spot that were observed throughout the study
- This combination in-office and at-home regimen was consistently highly rated by participants

RESULTS

Participant Disposition and Demographics

- 18 women enrolled; 17 completed the study
 - Race/Ethnicity: 56% White/Caucasian, 39% Asian, 6% Hispanic
 - Fitzpatrick skin type: I, 11%; II, 6%; III, 67%; IV, 17%

DGHP Plus the Take-Home Regimen of LYT3 + Spot Tx Achieved Rapid and Sustained Improvements in Investigator Assessments of Skin Quality




* $P < 0.05$ vs baseline (Student's paired t test).

- Significant improvements versus baseline immediately after 1 DGHP treatment were observed for skin hydration measured by Corneometer (mean change, 13.0), MoistureMeter XS (mean change, 3.0), and MoistureMeter S (mean change, 3.2; all $P \leq 0.01$ vs baseline, Student's paired t test)

METHODS

Study Design: a 12-Week, Open-label, Single-Center Study




Study assessments were performed at baseline, immediately after DGHP treatment, day 3, and weeks 2, 4, 6, 8, 10, and 12. *At-home regimen also included Facial Cleanser (AM/PM), Replenish Hydrating Cream (AM/PM), and Essential Defense Mineral Shield SPF 35 (AM and as needed).

Participants


- Females 18–65 years of age (Fitzpatrick skin type [FST] I–VI) with mild to severe facial HP (score of 3–9 on a modified Griffiths 10-point scale); ≥ 15 participants with moderate/severe overall HP
- 3–5 participants with mild overall hyperpigmentation

Improvements From Baseline in (A) Standardized Imaging and (B–D) Antera 3D Imaging Assessments of Participants' Most-Bothersome Spot Were Observed Throughout the Study


A. VISIA Standard Imaging




B. Color Analysis




C. Pigmentation Level and Uniformity




D. Pore count




DiamondGlow HP in Combination With LYT3 and Spot Tx Improved Appearance in a Patient With HP



Subject Self-assessment Showed Favorable Perception of Treatment Effects Immediately Following DGHP Treatment



Subject Self-assessment Showed Favorable Perception of Treatment Effects at Week 12



*At week 10.

- $\geq 93\%$ of subjects were satisfied with the DGHP plus LYT3 + Spot Tx results from week 2 onward

Tolerability Assessments

- Treatment was well tolerated, with mean tolerability scores of ≤ 1.4 for erythema and < 1.0 for dryness, burning/stinging, and itching at all time points (0–3 scale, where 0=none, 1=mild, 2=moderate, and 3=severe)